Lee Hambright
Stock Analyst at Bernstein
(2.64)
# 1,922
Out of 4,765 analysts
22
Total ratings
68.75%
Success rate
9.6%
Average return
Main Sectors:
Stocks Rated by Lee Hambright
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDT Medtronic | Maintains: Outperform | $96 → $97 | $92.33 | +5.06% | 2 | Nov 20, 2024 | |
| PODD Insulet | Initiates: Outperform | $300 | $244.67 | +22.61% | 1 | Nov 6, 2024 | |
| TNDM Tandem Diabetes Care | Initiates: Outperform | $42 | $18.18 | +131.02% | 1 | Nov 6, 2024 | |
| DXCM DexCom | Maintains: Outperform | $82 → $86 | $68.48 | +25.58% | 2 | Oct 25, 2024 | |
| BSX Boston Scientific | Maintains: Outperform | $92 → $100 | $95.37 | +4.85% | 1 | Oct 24, 2024 | |
| ABT Abbott Laboratories | Maintains: Outperform | $133 → $138 | $129.89 | +6.24% | 2 | Oct 17, 2024 | |
| ISRG Intuitive Surgical | Maintains: Outperform | $350 → $365 | $476.78 | -23.44% | 2 | May 31, 2023 | |
| ZBH Zimmer Biomet Holdings | Maintains: Market Perform | $136 → $152 | $107.57 | +41.30% | 1 | May 3, 2023 | |
| JNJ Johnson & Johnson | Downgrades: Market Perform | $183 | $162.99 | +12.28% | 4 | Mar 16, 2022 | |
| SYK Stryker | Upgrades: Outperform | $288 → $295 | $363.66 | -18.88% | 3 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $132 → $135 | $67.95 | +98.68% | 3 | Mar 16, 2022 |
Medtronic
Nov 20, 2024
Maintains: Outperform
Price Target: $96 → $97
Current: $92.33
Upside: +5.06%
Insulet
Nov 6, 2024
Initiates: Outperform
Price Target: $300
Current: $244.67
Upside: +22.61%
Tandem Diabetes Care
Nov 6, 2024
Initiates: Outperform
Price Target: $42
Current: $18.18
Upside: +131.02%
DexCom
Oct 25, 2024
Maintains: Outperform
Price Target: $82 → $86
Current: $68.48
Upside: +25.58%
Boston Scientific
Oct 24, 2024
Maintains: Outperform
Price Target: $92 → $100
Current: $95.37
Upside: +4.85%
Abbott Laboratories
Oct 17, 2024
Maintains: Outperform
Price Target: $133 → $138
Current: $129.89
Upside: +6.24%
Intuitive Surgical
May 31, 2023
Maintains: Outperform
Price Target: $350 → $365
Current: $476.78
Upside: -23.44%
Zimmer Biomet Holdings
May 3, 2023
Maintains: Market Perform
Price Target: $136 → $152
Current: $107.57
Upside: +41.30%
Johnson & Johnson
Mar 16, 2022
Downgrades: Market Perform
Price Target: $183
Current: $162.99
Upside: +12.28%
Stryker
Mar 16, 2022
Upgrades: Outperform
Price Target: $288 → $295
Current: $363.66
Upside: -18.88%
Mar 16, 2022
Upgrades: Outperform
Price Target: $132 → $135
Current: $67.95
Upside: +98.68%